ADMA Files Biologics License Application For Its Third Plasma Collection Center

Dec 11, 2017 12:08 pm UTC| Business

RAMSEY, N.J. and MARIETTA, Ga., Dec. 11, 2017 -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets...

Top Load Cartoning Machines Market to surpass a valuation of US$ 700 Mn by 2026 - FMI

Dec 11, 2017 12:01 pm UTC| Business

Valley Cottage, NY , Dec. 11, 2017 -- As per the latest report compiled by Future Market Insights (FMI), the global market for top load cartoning machines is likely to witness moderate growth. The market is projected to...

Masergy Streamlines Enterprise Cloud Transition With SD-WAN Enhancements

Dec 11, 2017 12:01 pm UTC| Business

DALLAS, Dec. 11, 2017 -- Masergy, a leading provider of hybrid networking, managed security and cloud communications solutions, has announced significant enhancements to its Managed SD-WAN Go solution. Upgrades include...

Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Dec 11, 2017 12:01 pm UTC| Business

PRESS RELEASE Immunocore's IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma (Oxford, UK and...

Faron Pharmaceuticals Oy: Recruitment completed in Traumakine INTEREST Trial

Dec 11, 2017 12:01 pm UTC| Business

Faron Pharmaceuticals Ltd("Faron" or the "Company") Recruitment completed in Traumakine INTEREST Trial The upcoming read-out will collate intact 90 day morbidity/mortality data alongside 28 day mortality data...

uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

Dec 11, 2017 12:01 pm UTC| Business

– Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity at Up to Two Years of Follow-Up – – Second Dose Cohort Demonstrated 89% Reduction in Spontaneous Bleeds, with No Confirmed...

Spark Therapeutics and Pfizer Announce Longer-term Preliminary Data Showing Consistent and Sustained Factor IX Levels in Hemophilia B at 59th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 11, 2017 12:01 pm UTC| Business

Data include eleventh participant in the trial Annualized...